From: Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
Characteristics | Acute renal failure with febuxostat as the suspected drug (n = 317) | Acute renal failure with allopurinol as the suspected drug (n = 1008) |
---|---|---|
Age, years, mean (SD) | 68.0 (15.0) | 67.0 (14.5) |
Age, n (%) | ||
19–44 | 27 (8.5) | 79 (7.8) |
45–64 | 83 (26.2) | 306 (30.4) |
65–74 | 81 (25.6) | 270 (26.8) |
≥ 75 | 126 (39.7) | 353 (35.0) |
Sex, n (%) | ||
Male | 172 (54.3) | 577 (57.2) |
Female | 145 (45.7) | 431 (42.8) |
Reporter qualification, n (%) | ||
Healthcare professional | 281 (88.6) | 863 (85.6) |
Not a healthcare professional | 17 (5.4) | 41 (4.1) |
Unknown | 19 (6.0) | 104 (10.3) |
The only suspected drug, n (%) | 184 (58.0) | 447 (44.3) |
Continent, n (%) | ||
North America | 115 (36.3) | 233 (23.1) |
Europe | 115 (36.3) | 489 (48.5) |
Asia | 82 (25.9) | 237 (23.5) |
Other regions* | 5 (1.6) | 49 (4.9) |
Seriousness of ARF | ||
Death | 22 (6.9) | 97 (9.6) |
Life-threatening event | 32 (10.1) | 111 (11.0) |
Disability/incapacity | 18 (5.7) | 13 (1.3) |
Hospitalization (caused or prolonged) | 115 (36.3) | 482 (47.8) |
Others | 70 (22.1) | 111 (11.0) |
Unknown | 60 (18.9) | 194 (19.2) |